Cost Effectiveness Analysis

Could earlier surveillance after TAVR unlock better outcomes at lower cost? 💡📈 A new analysis finds that proactive early‑post‑TAVR surveillance has the potential to be cost‑effective — and in many modeled scenarios, economically dominant — by improving patient outcomes while reducing downstream costs. The piece highlights key assumptions, sensitivity analyses, and implications for clinicians, payers, and policymakers. Read the full article to understand the evidence and what it means for adopting early surveillance strategies. #SyenzaNews #HealthEconomics #HealthTechnology #costeffectiveness #MarketAccess

🩺 Could we finally delay the onset of Type 1 diabetes? NICE has recommended teplizumab for people at high risk (stage 2), marking a potential first disease‑modifying option that can postpone progression to clinical disease — a decision driven by trial benefit, patient selection and cost‑effectiveness considerations. Read the full #SyenzaNews analysis to understand what this means for clinicians, payers and patients — and how implementation might unfold. #SyenzaNews #pharmaceuticals #HealthEconomics #healthcarepolicy #costeffectiveness

Is tovorafenib ready to change the treatment landscape for RAF‑driven cancers? 🔬📈 Our clinical assessment highlights promising early activity in select cohorts but flags key evidence gaps — limited randomized comparisons, immature long‑term safety and durability data, uncertain biomarker validation, and scarce real‑world outcomes that could affect regulatory and payer decisions. Read the full analysis to see prioritized evidence‑generation strategies and trial/design recommendations to support approval, reimbursement, and clinical adoption. #SyenzaNews #oncology #clinicaltrials #MarketAccess #healthcarepolicy

Could data-driven care pathways transform treatment for major depressive disorder? 🧠 This article outlines how treatment-pathway modeling uses patient data and simulation to identify optimal sequencing, improve remission rates, and guide resource allocation—balancing clinical outcomes with economic impact. It highlights practical implications for clinicians, payers, and policymakers seeking more personalized, cost-effective MDD care. Read the full analysis to explore the models, key findings, and next steps for implementation. #SyenzaNews #AIinHealthcare #HealthTech #innovation #costeffectiveness

Could counselling plus modest incentives be the missing piece to improving TB treatment adherence? New evidence shows that targeted counselling combined with small financial or non-financial incentives significantly raises treatment completion and cuts default rates, offering a practical, cost-effective option for TB programmes. The findings point to clear implementation and policy steps that can boost outcomes and reduce transmission. Read the full article to see the data, implementation tips, and the economic case for scale-up. 🔍 #SyenzaNews #globalhealth #HealthEconomics #healthcarepolicy #costeffectiveness

Could NICE’s new guidance on mirvetuximab reshape care for ovarian cancer patients? 🔬 NICE’s review of mirvetuximab soravtansine for FRα‑positive, platinum‑resistant ovarian cancer clarifies clinical and cost‑effectiveness considerations, eligibility criteria, and the remaining evidence gaps — with direct implications for clinicians, commissioners, and manufacturers. This analysis breaks down what the guidance means for treatment pathways and market access. 📈 Read the full article to see the practical takeaways and next steps for stakeholders. #SyenzaNews #oncology #drugdevelopment #healthcarepolicy #MarketAccess

Could NICE's approval of durvalumab reshape gastric cancer care in the UK? NICE has recommended durvalumab for gastric cancer after an appraisal that weighed clinical benefit and cost-effectiveness, opening the door to broader NHS access and changes to treatment pathways. The article explains the decision drivers, likely timelines for patient access, and implications for clinicians and industry. Read the full piece to get the details and what to expect next. 🔍 #SyenzaNews #oncology #regulatoryaffairs #MarketAccess #healthcarepolicy

🌟 How are Merck's advancements in oncology reshaping cancer treatment? With significant new data set to be unveiled at ASCO 2026, Merck is enhancing treatment options for cancers like melanoma and lung cancer, demonstrating long-term survival benefits through innovative therapy combinations. Dive into the insights from their presentations and discover how these breakthroughs could impact patient care. #SyenzaNews #oncology #drugdevelopment #HealthcareInnovation

Could marstacimab reshape hemophilia care in Portugal? 📊 A new cost‑effectiveness analysis models marstacimab versus standard prophylaxis and finds it may deliver better bleed prevention and quality‑adjusted life‑years at an acceptable incremental cost, with meaningful implications for budget impact and reimbursement decisions. The results give payers, clinicians, and policymakers clearer evidence to inform market access strategies. Read the full analysis to review the assumptions, sensitivity checks, and what this could mean for patients and the health system. #SyenzaNews #HealthEconomics #pharmaceuticals #costeffectiveness #Economicevaluation

Can faster assessments unlock patient access to high-cost medicines? ⏱️ A Dutch institute has shortened evaluation timelines for high-cost drug reviews by streamlining processes and improving stakeholder coordination, boosting predictability for manufacturers and potentially speeding patient access while keeping evidence standards central. Read the full article to learn which operational changes were made and what this means for market access and healthcare decision‑making. 🔍 #SyenzaNews #regulatoryaffairs #HealthEconomics #MarketAccess #healthcarepolicy

Could a new therapy change the treatment landscape for myasthenia gravis? 💊 NICE has endorsed rozanolixizumab, introducing another evidence-based treatment option that could shift clinical pathways and improve access for eligible patients. The decision also carries implications for payers and prescribing practices across the NHS. Read the full article to learn what the recommendation covers and what it means for patients, clinicians, and market access. #SyenzaNews #pharmaceuticals #clinicaltrials #MarketAccess #healthcarepolicy

What if HTA decisions could be tracked in real time? 🔍📊 Infarmed’s new real-time Health Technology Assessment tracker brings greater transparency to appraisal timelines, evidence and outcomes. It gives manufacturers, payers and policymakers the data needed to anticipate market access, streamline submissions and improve planning. Read the full article to see how the tracker works and what it means for regulatory strategy and market access. #SyenzaNews #HealthTechnology #regulatoryaffairs #MarketAccess #DigitalTransformation